– Zentiva, a leading European generics pharmaceutical company, is being sold by Advent to GTCR.
– Advent acquired Zentiva from Sanofi in 2018 and transformed it into a successful standalone business.
– Investments by Advent expanded Zentiva’s medicine portfolio and manufacturing footprint through organic growth and targeted M&A.
– Zentiva now has strong operational excellence and R&D capabilities, serving millions of patients across Europe.
– GTCR is a global private equity firm with a strong track record in healthcare and pharmaceuticals.
– GTCR has invested in several leading pharma platforms and completed dozens of acquisitions in the past 20 years.
– With its expertise, GTCR is well-positioned to support Zentiva’s next growth phase through organic expansion, product innovation, and strategic acquisitions.
– Steffen Saltofte, CEO of Zentiva, credited Advent for its instrumental role in growth and expressed excitement about partnering with GTCR.
– Tom Allen, Managing Director at Advent, highlighted that Zentiva has more than doubled its revenue and EBITDA since 2018 and became a European leader in affordable medicines.
– Sean Cunningham, Managing Director and Head of Healthcare at GTCR, emphasized Zentiva’s strong pipeline, efficient manufacturing, and mission to deliver high-value medicines.
– The transaction is subject to regulatory approvals, expected to close in early 2026.
– Advisors:
▪️Advent: Goldman Sachs and PJT Partners (financial), Freshfields (legal).
▪️GTCR: Barclays and BNP Paribas (lead financial), Morgan Stanley (financial), Kirkland & Ellis (legal).
